Stempoint Capital’s Relmada Therapeutics RLMD Stock Holding History

Stempoint Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1M	Buy	1,460,093 +862,684	+144%	+$6.03M	1.74%	22
2026 Q1	$4.16M	Buy	+597,409	New	+$2.83M	0.8%	40

Other funds holding RLMD

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stempoint Capital's RLMD Position: Q2 2026 in Review

Stempoint Capital increased its Relmada Therapeutics (RLMD) stake by 144% in Q2 2026, buying an estimated $6.03M and bringing the position to 1,460,093 shares worth $10.1M. The position accounts for 1.74% of the portfolio, ranked #22.

Stempoint Capital first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

Stempoint Capital held 1,460,093 shares of Relmada Therapeutics worth $10.1M as of Q2 2026.
Stempoint Capital bought 862,684 Relmada Therapeutics shares in Q2 2026, an estimated $6.03M.
Relmada Therapeutics made up 1.74% of Stempoint Capital's portfolio in Q2 2026, its #22 holding.
Stempoint Capital first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.